ImmuneOnco Biopharmaceuticals – HK$319 Million IPO
September 5, 2023
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.
Cooley advised the joint sponsors and underwriters of Cryofocus Medtech’s HK$210 million ($27 million) initial public offering of 11,110,000 H Shares on the Hong Kong Stock Exchange.
